Pharmacyclics, Inc. (NASDAQ:PCYC)
CAPS Rating:
A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
Get rich slowly
A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Skyrocketed based on expectations; no tangible results & more lofty expectations based on today's valuation compared to most other biotechs
This appears to be a now, sour-pick; I would not short this. This pick will remain open to simply track this long-term.
Sources are citing their cancer treatment could be worth up to $1 billion and future royalties.
With their cancer treatment, they have a high profile partnership with a Johnson & Johnson (NYSE:JNJ) subsidiary (Janssen Biotech).
In the recent quarter, they raked in ~$60million. And ended the qtr with $240 million in cash.